key: cord-0699714-ahceohgl
authors: Hassan, Mohd. Zaheen; Osman, Hasnah; Ali, Mohamed Ashraf; Ahsan, Mohamed Jawed
title: Therapeutic potential of coumarins as antiviral agents
date: 2016-11-10
journal: Eur J Med Chem
DOI: 10.1016/j.ejmech.2016.07.056
sha: a0a5fe6805a6a370e31628c78c5803eeb38093f9
doc_id: 699714
cord_uid: ahceohgl

Coumarins have received a considerable attention in the last three decades as a lead structures for the discovery of orally bioavailable non-peptidic antiviral agents. A lot of structurally diverse coumarins analogues were found to display remarkable array of affinity with the different molecular targets for antiviral agents and slight modifications around the central motif result in pronounced changes in its antiviral spectrum. This manuscript thoroughly reviews the design, discovery and structure–activity relationship studies of the coumarin analogues as antiviral agents focusing mainly on lead optimization and its development into clinical candidates.

Viruses are causative agents for several epidemic fatal diseases such as human immunodeficiency virus (HIV), hepatitis B and C viruses (HBV and HCV, respectively), coronaviruses (Middle east respiratory Syndrome, MERS; severe acute respiratory syndrome, SARS), influenza (seasonal, pandemic), smallpox, viral haemorrhagic fevers (Ebola), dengue, and chikungunya etc. Each of these diseases has caused global societal and economic impact related to unexpected illnesses and deaths, as well as troubling day-to-day normal life activities. Recent emergence of newer pandemics e.g. H1N1 influenza, Ebola, and Zika virus etc. are also a major threat to public health [1, 2] . All these emerging viruses have more or less RNA genomes and as a result are capable of rapid mutation and resistance to the clinically available antiviral drugs. Thus threat of resistance poses major challenges in clinical management of these viral infections [3] . However, the field of antiviral drug discovery has witnessed a steady flow of exciting developments since the advent of nucleoside analogue acyclovir in 1960 [4] . Subsequently, more than 60 antiviral drugs of diverse chemical classes have been approved by the FDA, mainly for the management of HIV, herpes, the hepatitis B and C, and influenza A and B viruses and still many molecules are in various stages of clinical trials. Despite of these progress in the development of antiviral agents in recent years, there is still a pressing need for newer drugs acting through different mechanism to combat the problem of viral resistance as viruses are constantly evolving and have been developing new ways to evade the drugs [5] . Moreover, all of these render the search of antiviral therapy indistinct since it is difficult to identify unique biochemical features of viruses that may be appropriate for selective attack without harming the host cells [6] .

Coumarins (benzo-a-pyrone) are considered as a privileged structure for designing novel agents having high affinity and specificity to different molecular targets for antiviral agents [7] . Because, coumarins are endowed with a unique characteristic pharmacophore of planar aromatic nucleus connected with a hydrogen bond acceptor; lactone group as a facilitator of proteinligand binding [8] . Coumarins have gained momentous attention in the last three decades as a lead structures for the discovery of orally bioavailable non-peptidic antiviral agents. Several of natural, semisynthetic, synthetic lead molecules bearing coumarin scaffold Previously, more or less all the clinically available HIV protease inhibitors are pepetidomimetics. Although these peptide-based inhibitors have got the edge over other inhibitors because of their very high binding affinity, but generally lacking the bioavailability requirements essential for cellular and oral activity and metabolic instability. This led to the search for inhibitors containing nonpeptidic templates that might offer superior biopharmaceutical properties. 4-hydroxycoumarins (4-HCs) as non-peptidic HIV protease inhibitors have received considerable attention in the 90s, owing to their low molecular weight, high oral bioavailability, low clearance and more importantly, these are already being in use as therapeutic agents in human. Warfarin (1) is a 4-HC analogue, which is clinically available drug used in the prevention of thrombosis and thromboembolism. It acts by inhibiting vitamin Kdependent conversion of prothrombin into an active form thrombin, which is a serine protease enzyme catalysing many other coagulation-related reactions [17] . Moreover, several studies demonstrate that the protease is also an essential viral enzyme and an attractive target for anti-HIV drugs [18] . Prompted by these correlations, Bourinbaiar and his colleagues pioneered the study of testing the effects of the oral anticoagulant, warfarin, on viral replications and spread. Remarkably, they found that the low doses of warfarin (10 À9 to 10 À8 M) effectively inhibited the 50% HIV infections [19] . This discovery of 4-HC as a lead compound having promising anti-protease activity pave the way for the development of a new class of non-peptidic oral anti-viral agents. In pursuit of this goal, the Upjohn laboratory scientists Thaisrivongs et al. evaluated some similar coumarin derivatives as potential HIV-protease inhibitors using fluorescence based high-throughput screening. Surprisingly, an another coumarin based anticoagulant phenprocoumon (2) emerged as a novel lead template possessing weak HIV protease inhibitory activity (K i ¼ 1 mM) with antiviral ED 50 of 100e300 mM but having superior pharmacokinetics (Fig. 2) . Protein crystallography of 2 in complex with HIV-1 protease was successfully carried out in order to get a clear insight of interactions and lead optimization. This crystal structure revealed that the 4-HC scaffold binds in a mode very similar to that of peptide inhibitors at the catalytic site, with the C-4 hydroxyl forming two hydrogenbonds with aspartic residues (Asp25A and Asp25B) and lactone group forming two hydrogen bonds with isoleucine residues (Ile50A and Ile50B) (Fig. 3 ). This study led to the postulation of 4-HC as an essential pharmacophoric element which formed the basis of ensuing structure based drug design of more active analogues.

Structure-based drug discovery (SBDD) is becoming an essential tool in assisting fast and cost-efficient lead discovery and optimization, as it aims to understand the molecular basis of a disease and utilizes the knowledge of the 3-D structure of the biological target in the process. Using the SBDD approach and X-ray crstallography, the 4-HC template was further optimised and developed into the first clinical candidate 4-hydroxy-2-pyrone derivative U-96988 (3) as non-peptidic HIV protease inhibitor which entered phase I clinical trials (Fig. 4) . Compound 3 showed excellent HIV-1 protease inhibition (K i ¼ 38 nM), significant antiviral activity (IC 50 ¼ 3 mM) and improved pharmacokinetic properties and thus considered as a potential therapeutic agent for the treatment of HIV infection [20] .

Molecular hybridization of different pharmacophoric subunits, is an important tool for lead optimization and have provided the discovery of numerous ligands with synergistic properties. Based on these approach Thaisrivongs and co-workers (Upjohn Lab.) did an extensive research and examined the crystal structure of 4-HC analogues bound to HIV protease superimposed along with previously reported peptide-based inhibitors (4). The relative positioning of peptidic and non-peptidic compounds in HIV-protease revealed that addition of amide chain at the meta position of the phenyl ring of 4-HC could improve the binding affinity of coumarin-based inhibitors. This design strategy resulted into an exciting series of a several promising amino acid and non-amino acid residue containing 4-HCs (5e10) with improved enzymebinding affinity. These study revealed that, in addition to the essential pharmacophore 4-HC, 5,6-dihydro-4-hydroxy-2-pyrones incorporated side chains at the C-6 position are also suitably accommodated into the S1 0 and S2 0 subsites of the enzyme active site. Thus, previously reported compound 3 also provided a basis for possible further modification of these series into potent 2pyrone analogues. Consequently, pyrone compound containing Lhistidyl amino acid residue (11) , was found to be most potent analogue of the series having K i ¼ 4 nM. Further resolution of its four specific diastereomers had no significant impact on enzymebinding affinity which clearly indicates their insignificant stereochemical preferences. Cell culture assay proved the compound as a nontoxic (TD 50 ¼ >>30 mM) with antiviral potency of IC 50 value 3e6 mM, which is comparable to that previously reported for the inhibitor 3 (Fig. 5 ) [21] . Replacement of ethyl group by cyclopropyl group at C-3a position has also resulted in compounds 12e15 with improved efficacies. The general SAR of the series has been illustrated in Fig. 6 . Romines et al. at the Upjohn laboratories demonstrated a unique strategy for the enhancement secondary binding of 4-HC inhibitors to the protease enzyme. Instead of pursuing 4-hydroxy-2-pyrones they explored an alternate strategy for increasing the flexibility by replacing the benzene ring of 4-HC with saturated cycloalkyl rings i.e. cyclopentylpyranone (16) and cyclooctylpyranone (17) (Fig. 7) . The results were surprising and cyclopropyl containing cyclooctylpyranone (18) emerged as a potential protease enzyme inhibitor having good pharmacokinetics but relatively very low activity in cell culture (IC 50 ¼ 57 mM). The size variation of cycloalkyl ring also provided some interesting information about the binding mode of conformationally-flexible cyclooctyl ring on the inhibitors [22] . Further, they also designed some meta substituted carboxamide derivatives (19 and 20) which were significantly more active than the corresponding unsubstituted cyclooctylpyranone due to its additional hydrogen bonding by the amide group [23] . Substitution of cyclooctylpyranones with a wide variety of arenesulfonamides led to analogues with markedly enhanced antiviral Resolution via chiral HPLC yielded more potent enantiomer having a K i ¼ 0.6 nM and an antiviral IC 50 ¼ 1 mM. Oral bioavailability of this compound ranged from 42% (rat) to 77% (dog) with t 1/2 ¼ 6 h [24, 25] . Saturation of the 5,6-double bond in the pyrone ring led to the identification of a cycloalkyldihydropyrone derivative (22) with superb binding affinity for the HIV protease (K i values in the 0.05 nM) and excellent antiviral activity in cell culture, with significantly less ED 50 value of 0.95 mM [26] . Unfortunately, all the previous agents (U-96988 and U-103017) had failed in the early 1990s, but Pharmacia & Upjohn (now Pfizer) was again successful in generating buzz in June of 1999 when they reported the promising results of its new compound tipranavir (PNU-140690) (23), a potent orally bioavailable HIV-1 protease analogue of the 5,6dihydro-4-hydroxy-2-pyrones sulfonamide class (K i ¼ 8 pM) effective against the 96 out of 107 highly resistant strains [27] . Later in the year 2000, Boehringer Ingelheim (BI) acquired the exclusive rights to tipranavir (Aptivus ® ) and subsequently, it was approved by the US FDA in 2005. A group of scientist Tummino et al. also did a parallel research for the development of non-peptidic inhibitor. They screened the Parke-Davis compound library using a high through-put assay and identified phenoxypropyl derivatives of 4-HC (PD099560) (24) and phenylthio derivative of 4-hydroxypyrone (25) as reversible competitive inhibitors effective at micro molar level. These two derivatives were excellent lead molecules in the development of therapeutically effective HIV-1 protease inhibitors, since they are small achiral nonpeptide molecules which can be easily synthesized and possessed promising pharmacological properties [28] . Binding mode of the compounds were studied employing a Monte Carlo-based docking procedure and X-ray crystal analysis. Subsequently, several analogues were prepared to test the binding interactions and improve the overall binding affinity. Amongst all, 4,7-dihydroxy-3-(4-(2-methoxyphenyl)butyl)-2H-chromen-2-one (26) emerged as the most active compound having IC 50 0.52 mM.

Further optimization of pyrone derivative yielded several potent analogues (27e32) having several fold higher binding affinity among which PD-178390 (31) EC 50 of 200 nM) was selected for further preclinical evaluation [29e34]. Unfortunately, no further clinical progress of this compound has been reported, probably as a consequence of the merging of the company with Pfizer. Parke-Davis laboratories also identified a dimethyl derivative of warfarin (32) which was nine-fold more potent than the parent compound (IC 50 value 1.9 m M) but later they did not pursue warfarin analogues (Fig. 8 ) [35] .

Collaborative endeavours of 3D database searching by Wang's group at the Laboratory of Medicinal Chemistry, and the Frederick Cancer Research and Development Centre, National Cancer Institute (NCI-US), resulted in a group of eight promising non-peptide HIV-1 protease inhibitors of 4-HCs along with some other class of compounds (33e40) (Fig. 9 ). The pharmacophore query used in the search was derived directly from the X-ray crystallography structures of protease-inhibitor complexes. Results of the in-vitro HIV protease bioassay evaluations clearly suggested that, while compounds containing a single 4-HC moiety are capable of binding to HIV-1 protease, compounds such as NSC 32180 (33) (ID 50 0.32 mM) and 158393 (40) (ID 50 1.7 mM, IC 50 11.5 mM), which contain a "dimer" or "tetramer" of 4-HC, may be superior leads for further development. Compound NSC 158393 was also found to be an inhibitor of HIV-1 integrase and HIV-1 reverse transcriptase (RT). This compound therefore represents a multi-target lead for the development of potential anti-AIDS drugs. Based on their structural studies, they also proposed a pharmacophore essential for the HIV protease activity [36] . Further optimization of lead molecule NSC 158393 into structurally simpler coumarin derivatives through fragmentation of tetramer revealed that a coumarin dimer containing an arylmethylene (41) is an essential HIV Integrase pharmacophore [37] . Indeed, it turned out that modification of central phenyl ring with more lipophilic extended aromatic systems and addition of 7-hydroxy substituents to the coumarin rings (42) significantly enhanced its potency [38] .

Considering the conspicuous significance of 4hydroxycoumarinic derivatives as HIV-1 protease inhibitor, Kirkiacharian and co-workers have synthesized some sets of 3substituted 4-HCs (43) with the objective to investigate the influence of some modifications at the 3-position of coumarin. The results demonstrated that any hydroxyl group nearer to the 4hydroxyl group interfere with the hydrogen bond between this group and Asp25/Asp25 0 of HIV-1 protease however, distant 7hydroxy derivatives were most active anti-HIV agents. Replacement of 3-phenyl with benzyl group indicates that flexibility did not lead to any significant change in activity [39] . Similarly, another scientist Stanchev et al. also reported some 4-HC derivatives as HIV-1 protease inhibitors. All these compounds were tested for anti-HIV-1 protease activity in MT4 cells infected by HIV-1. The highest inhibition of HIV-1 PR (25%) and highest MT4 cell survival (78%) were demonstrated by compound containing m-nitrophenyl derivative (44) (Fig. 10 ) [40] .

In an effort to identify novel anti-HIV agents from natural sources, Huang et al. reported a new class of tricyclic coumarin anti- HIV suksdofin, [(3 0 R,4 0 R)-3 0 -acetoxy-4 0 -(isovaleryloxy)-3 0 ,4 0 -dihydroseselin] (45) which is a pyranocoumarin derivative having two cis-oriented acyl groups at the 3 0 and 4 0 positions obtained from the plant of Lomatium suksdorfii (Umbelliferae) as an anti-HIV agent [41] . The structures of suksdorin and related coumarin derivative pteryxin (46) was previously established by Willetti et al. [42] . Suksdorfin was found to inhibit HIV-1 replication in H9 lymphocytes with an in vitro EC 50 value of 2.26 mM and a therapeutic index value of 30.6. They observed that varying the acyl groups at 3 0 and 4 0 positions of pyran ring greatly affect the anti-HIV potency of unsubstituted analogue seselin (47) . This led to discovery of first 48) , showing extremely potent inhibitory activity (EC 50 ) 2.56 ± 10 À4 mM) against HIV-1 replication in the H9 cell line and had a remarkable therapeutic index (TI ¼ 136719) however, its other diastereoisomers were 10000 times less active [43] . Enthused by their promising early findings, Lee et al. reported numerous DCK analogues and its thorough structure-activity relationship (SAR) which demonstrates that, 3 0 R,4 0 R configurations and planarity of the coumarin ring system are essential structural features for anti-HIV activity; alkyl/O-alkyl substituents at the 3-, 4-, and 5-positions on the coumarin are favourable for enhanced anti-HIV activity and decreased toxicity of DCK [44e48]. However, development of DCK-analogues as effective anti-AIDS drugs has been hindered by problems of their low water solubility hence less bioavailability and their ineffectiveness against multidrug resistant HIV strains (RTMDR). Therefore, in furtherance to the development of DCK-related clinical drug candidates (49e51) they identified hydroxymethyl derivative of DCK (49) as first moderate orally bioavailable drug (water soluble, F ¼ 15%) which acts inhibiting the production of double-stranded viral DNA from the single-stranded DNA intermediate [49] . Moreover, ring opened DCK analogues or seco-DCK (52) which contains lesser hydrogen bond acceptor also showed improvement in ADME properties and found to be effective against RTMDR strains [50] . Isomeric replacement of coumarin with chromone resulted in DCP analogues (53) which are potent anti-HIV agents against the resistant strains RTMDR [51] . Seco-DCP (54) and extended conjugated xanthenone analogues (55) were also turned out to be promising against these untreatable resistant strains (Fig. 11) [52, 53] .

The discovery and development of the anti-HIV compounds calanolide A and its analogues is an interesting account of lead identification that brought a promising drug candidate to patients with HIV while addressing the challenging issue of drug resistance. In 1992, Kashman and co-workers at the NCI laboratory discovered a new class of coumarin derivatives known as calanolide from the tropical rainforest tree, Calophyllum lanigerum as anti-HIV chemotype. Calanolides (A, B and C) (56e58) are chemically tetracyclic dipyranocoumarins having three chiral carbon centres in the scaffold at the C-10, -11, and -12 positions. Studies with purified bacterial recombinant reverse transcriptases (RT) revealed that these calanolides are HIV-1 specific RT inhibitors active against both AZTresistant G-9106 and pyridinone-resistant A17 strain. A 5-fold reduction in activity was observed for the 12-keto analogue 59 which contains one lesser chiral centre. Thus calanolides represent a substantial departure from the known class and therefore provide a novel new anti-HIV chemotype for drug development [54] . Because of their limited availability from natural resources, the total synthesis and racemic resolution of calanolides has been carried out. After bioassay, only (þ)-calanolide A (NSC-675451) accounted for the anti-HIV activity, however its (À)-isomer was inactive [55] . Related novel RT inhibitors inophyllums A (60), B (61), C, E and P (62) were isolated from the fractions of Calophyllum inophyllum Linn. (Malaysian indigenous) [56] and cordatolide A (63) and B (64) were isolated from Calophyllum cordato-oblongum (a Srilankan indigenous) [57] . Prompted by these results, a number of closely related pyranocoumarins have been reported afterwards in different Calophyllum species and their semi-/synthetic derivatives (65e68) were also designed as potent anti-HIV agents [58e60]. Currently, (þ)-calanolide A (56) (Sponsor: Sarawak Med-iChem Pharmaceuticals) has completed phase I/II 48-subject clinical trial as combination therapy for HIV (Fig. 12) . The oral toxicity of the drug was minimal and reported adverse effects were dizziness, nausea, oily aftertaste. 

In search of natural anti-AIDS agents some furanocoumarins (69e77) have been isolated from the different plants viz. Ferula sumbul, and Prangos tschimganica (Fig. 13) [61, 62] . Among all the furanocoumarins, imperatronin (71) emerged as a promising anti-HIV agent. Imperatronin inhibited HIV replication in H9 lymphocytes with EC 50 values of <0.10 mg/ml, and it inhibited uninfected H9 cell growth with IC 50 values of >100 mg/ml, calculated therapeutic index (TI) value of >1000. Further studies on its mechanism of action revealed that unlike the other coumarins, imperatronin did not inhibit the reverse transcription nor the integrase but inhibit the Sp1-related genes (D1 expression) thereby arresting the cells at the G(1) phase of cell cycle. These results highlight the potential of SP1 transcription factor as a target of natural anti-HIV compounds, such as furancoumarins that might have potential therapeutic role in the management of AIDS [63] .

A Japanese research group led by Uchiumi et al. demonstrated that naturally occurring 3-phenylcoumarins (3-PC) compounds (78, 79) , generally present in tea leaves suppress TPA-induced HIV promoter activity. These compounds did not show any suppressive effect on the cytomegalovirus (CMV) promoter, suggesting that they act specifically on the HIV promoter. These results suggest that 3-phenylcoumarin derivatives might be potential candidate for developing novel anti-HIV drugs targeting at HIV promoter activity [64] . Encouraged by these observations, Olmedo et al. synthesized different 3-phenylcoumarin derivatives and evaluated their anti-HIV activity. The sulfanylphenylcoumarin derivative (80) emerged as the most potent inhibitor of HIV replication acting through dual inhibition of NF-kB and unspecific Tat functions whereas, 4hydroxy derivative (81) (umbelliferone derivative), acts through specific Tat inhibitory activity. All the synthetic coumarins were more potent than mesuol against both NF-kB and Tat molecular targets but less effective in the RV assay. Thus, the presence of prenyl or prenacyl substituents attached to coumarin nucleus could be prerequisite structural factor reinforcing the antiviral activity (Fig. 14) [65] . (Fig. 15 ). Detailed SAR and minimal pharmacophore responsible for Vpr inhibitory activity has also been explored. Binding assay of Vpr mutants revealed that the hydrophobic region about residues Glu-25 and Gln-65 are potentially involved in the binding of the inhibitor. Therefore, the study provides a new insight into molecular mechanism of Vpr-inhibitor which could be pragmatic for future drug development [66] .

Marquez et al. reported two natural 4-phenylcoumarins (4-PC), mesuol (84) and isomesuol (85) obtained from tree Marila pluricostata as effective anti-HIV agents acting through a novel mechanism of TNFa-mediated HIV-1-LTR transcriptional activity. These coumarins are devoid of the reverse transcription and intregration activity as like the other coumarins. Both the isomers suppress HIV-1 replication in Jurkat T cells with IC 50 ranging from 2 to 2.5 mM and complete inhibition at 15 mM however only mesuol exhibited a potent anti-HIV activity in peripheral blood mononuclear cells acutely infected with HIV-1 clone. Thus, 4-phenyl-coumarins which are acting through a novel mechanism could be a potential lead for the development of potent therapeutic agent in the management of AIDS and drug-resistant HIV strains [67] . Later scientist from the same laboratory reported two more compounds (86, 87) of same class, 4-PC as potent HIV transcription inhibitors acting mainly through interference of NF-kB and Tat functions (Fig. 16 ) [68]. Likewise, several other studies also proved that 4-PC can be considered as promising model compounds for developing novel HIV-1 inhibitors [69] .

The importance of the 4-HC pharmacophore for antiviral activity had been depicted in many studies. Therefore, Abd Elhafez et al. reported a series of thiazolidinone (88) , oxadiazoline (89) and hydrazone (90) containing coumarin derivatives as antiviral agents. Among all these, compound having p-chlorophenyl-thiazolidinone derivative had the highest activity and was able to reduce the number of plaques by 30% at a concentration of 0.12 mg/mL (MIC) having cytotoxicity CD 50 value 0.02 mg/mL [70] . Bhavsar et al., have also designed some novel anti-HIV agents by the molecular hybridization of coumarin-4-acetic acid and substituted 2-amino benzothiazoles. Most of these compounds showed moderate to potent activity against wild-type HIV-1 with an EC 50 ranging from >7 to <100 mg/mL. SAR demonstrate that substitution of coumarin nucleus with hydroxyl group increases the activity whereas, bulky group decreases the anti-HIV property. The most potent compound of the series was N-1,3-benzo[d]thiazol-2-yl-2-(2-oxo-2H-chromen-4-yl)acetamide (91) (EC 50 ! 7 mg/ mL) [71] (see Fig. 17 ).

A new class of marine compounds for potential development of clinically useful integrase inhibitors was obtained from didemnid ascidians. Chemically these are a group of DOPA-(2-amino,3-(3 0 ,4 0dihydroxyphenyl)propionic acid)-derived pyrrole alkaloids containing coumarin nucleus, commonly known as lamellarins. These compounds are effective against HIV-1 integrase protein which is an attractive target for anti-retroviral chemotherapy. Especially, a member of this family lamellarin a 20-sulfate (92) was found to inhibit integrase protein in vitro and viral replication in cultured cells. Its site of action on the integrase protein was also mapped by testing activity against deletion mutants of integrase [72] . Aesculetin (93) (esculetin, or cichorigenin), a dihydroxy derivative of coumarin obtained from the aerial part of Artemisia capillaris was also reported as an anti-HIV agent. It inhibited HIV replication in H9 lymphocyte cells with ED 50 values of 2.51 mg/mL and therapeutic index of 11.2 (Fig. 18 ) [73] .

Viral hepatitis is a potentially serious infectious disease mainly affecting liver causing hepatocellular carcinoma and is a major cause of morbidity and mortality worldwide. Therefore, recent research efforts have been more focusing on development of antiviral therapy and vaccination strategies against these viruses. Several coumarins analogues also proved to have a substantial anti-hepatitis virus activity. Recently a new compound library of hybrid coumarin-benzimidazole derivatives connected through inhibiting HCV RNA replication by 90% and had no effect on cell proliferation. These data in the new compound library provided clues for the development of several coumarin-benzimidazole related conjugates as anti-HCV agents [74] . Subsequent modifications of benzimidazole nucleus into heterobicycles; imidazopyridine, purine, benzoxazole, and benzothiazole were also carried out to establish the structure-activity relationship (SAR) on the basis of new compounds library. Most promising compounds were imidazopyridine-coumarin (96), purine-coumarin (97), and benzoxazole-coumarin (98), which inhibited HCV replication at an EC 50 of 6.8, 2.0, and 12 mM, respectively [75] . However, the benzothiazolyl-coumarin analogue (99) was least effective against the HCV. These encouraging results of purine-coumarin conjugates pave the way for the development of corresponding ribonucleoside-coumarin analogues. Seven among the 26 new compounds were found to inhibit HCV subgenomic replicon replication in the Huh 5e2 cell line. Amongst these purine analogues, 8-(Coumarin-3 0 -yl)methylthio-9-(b-D-ribofuranos-1 00 -yl)purine (100) showed potent activity with EC 50 value of 2.0 mM [76] . In another series, the benzimidazole ring was replaced by imidazole ring to further explore the SAR of imidazoleecoumarin conjugates (101). It was observed that unsubstituted imidazole (i.e. hydrogen atom at the N1 position) and Cl, F, Br, Me, and OMe substitution at the coumarin nucleus resulted into compounds having significant activity [77] . Removal of methylenethio linker between the benzimidazole and coumarin afforded directly hinged coumarin-benzimidazole derivatives as potent anti-HCV agents.

The dimethylimidazole-coumarin (102) and methylimidazole-benzocoumarin (103) exhibited promising EC 50 values of as low as 3.0 and 5.5 mM, respectively. Further incorporation of a D-ribofuranose afforded corresponding nucleoside (104) with slight abatement in activity [78] . Thus, all these detailed studies underline the significant potential of coumarinbenzimidazole conjugates as a lead compound for the development of novel therapeutic agents for the treatment of HCV (Fig. 19) .

Recently Manvar et al., 2016 have synthesized imidazo[1,2-a] pyridine-4-hydroxy-2H-coumarins (Fig. 20) as potential NS5B inhibitors. The ability of titled compounds to interact with protein was investigated by in silico screening against non-structural 5B (NS5B) viral protein. The hybrid coumarin derivative 105 interact with allosteric site of NS5B protein and exhibited a docked confirmation which was in good conformity with the reference ligand [79] .

Using the same methylcoumarin pharmacophore, Peng and coworkers designed some novel anilinocoumarin derivatives as agents against HCV. It was observed that substituents bearing a strong electron-donating motif on the phenyl ring were crucial for anti-HCV activity and trimethoxyanilino derivative (106) emerged as potent antiviral agent with EC 50 value of 12 mM (SI 10). The compound was found to act through a novel molecular mechanism by the induction of interferon-a (IFN)-mediated antiviral responses. Thus anilinocoumarin derivatives could be a lead compound in anti-HCV therapy for circumventing drug resistance due to HCV virus mutations (Fig. 21) [80].

A series of Mannich bases (108) of 7-hydroxycoumarins (osthole analogues, 107) were synthesized and evaluated as anti-flaviviridae in particular anti-HCV by Mazzei et al. An interesting pattern of SAR was observed among the different viruses. The 7-propyloxy derivatives were found to be active against bovine viral diarrhoea virus (BVDV) and 7-benzoyl derivatives were active against respiratory syncytial virus (RSV) whereas 7-hydroxy derivatives were ineffective against flaviviridae group of virus. Molecular docking studies revealed that DNA polymerase is potentially involved in the inhibition of HCV. Some unsymmetrical methylene derivatives 109e111 (namely coumarins bridged to chromones or indoles) were also reported as moderately active antiviral agents [81] . Another 7-hydroxycoumarins natural compound collinin (112), which is a geranyloxycoumarin isolated from the root bark of 

Basu et al. identified and characterized coumestans, an isoflavonoid class of phytoestrogens as a novel class of anti-NS5B agents. The hepatitis C virus (HCV) NS5B is essential for viral RNA replication and is therefore a key target HCV inhibitor. A naturally occurring coumestan, wedelolactone (113) exhibited NS5B RNAdependent RNA polymerase (RdRp) inhibition in micromolar range, which prompted them to synthesise another four different synthetic analogues (114e117). LQB34 (115) was found to be most effective NS5B inhibitor with IC 50 value of 18.5 mM (~2e20 fold active). They further concluded that the anti-NS5B efficacy of coumestans are inversely correlated with their hydrophobicity. Molecular docking studies revealed that, modification of benzofuran and coumarin core along with peripheral hydroxyl and methoxy groups will be valuable affording compounds which might be ideal inhibitors accommodating the NS5B binding pocket (Fig. 23 ) [83] . 

An angular furanocoumarin such as angelicin (118) was found to be safer pharmacophoric element for the anti-influneza activity. However, its linear analogue psoralen (69) is a highly phototoxic isomer due to its ability to cross-link deoxyribonucleic acid (DNA). A novel angelicin derivative 119 as potent influenza A (H1N1) virus inhibitor was identified by using a cell-based high-throughput screening of around twenty thousand compounds. The structural novelty of the hit molecule encouraged them to further pursue the lead-optimization of this class through SAR exploration. Thiophenoyl substituted angellicin (120) emerged as the optimised lead exhibiting 64-fold enhanced activity compared to hit. The compound was found to be broad spectrum anti-influenzal agent effective against both influenza A (H3N2) and influenza B strains same as drug zanamivir. Further plasmid-based reverse genetics using luciferase assay yielded key insight into the molecular mechanism of angellicin derivatives which point toward viral ribonucleoprotein (RNP) as a probable molecular target for these agents [84] . Later benzoyl substituted angelicin (121) (BPR2-D2) also emerged as a novel inhibitor against influenza virus exhibiting excellent antiviral efficacy against the oseltamivir-resistant virus (EC 50 ¼ 0.021e0.040 mM). BPR2-D2 also exhibited a broad antiviral spectrum against various strains of influenza A and influenza B viruses. The compound acts by targeting viral RNPs that are responsible for viral RNA synthesis [85] . This same molecule (BPR2-D2) was later established as an effective anti-HIV agent (BPRHIV001) which inhibits Tat-Mediated Transcription through Akt pathway (EC 50 ¼ 1.3 nM) [86] . Thus this molecule has the potential to become a promising lead compound for the development of a novel therapeutic agent effective against both HIV-1 and influenza infections (Fig. 24 ).

Over the years, many natural plant based compounds have been reported as potential antiviral agents effective against the Herpes simplex viruses (Fig. 25 ). In the year 1995, Ishikawa et al. isolated a unique coumarin-naphthoquinone dimer called toddacoumaquinone (122) from Toddalia asiatica (Rutaceae) and evaluated its antiviral activities against Herpes simplex virus type 1 (HSV-1), Herpes simplex virus type 2 (HSV-2) and human immunodeficiency virus type 1 (HIV-1). The compound was found to be weakly active against HSV (EC 50 ¼ 10 mg/mL) but was ineffective against HIV [87] .

Xu and colleagues have also demonstrated that inhibition of human herpesvirus 8 (HHV-8) replication could be achieved by the use of (þ) rutamarin (123) which is a natural furanocoumarin obtained from the plant Ruta graveolens L (common rue). In this study, a total of 7200 compounds were virtually screened for their topoisomerase II inhibition properties and subsequently tested for antiviral activities. Out of these, natural product (þ) rutamarin, exhibited significant inhibition of both viral DNA synthesis and virion cause of Kaposi's sarcoma (KS) and other AIDS-associated malignancies. Thus, (þ) rutamarin could be a potent clinical candidate for the treatment of human diseases associated with KSHV infection [88] . The sesquiterpene coumarin, kellerin (124) isolated from the gum resin of Ferula asafoetida significantly reduced the viral titre of the herpes virus type 1 (HSV-1) DNA viral strains KOS at concentrations of 10, 5 and 2.5 mg/mL with an inhibition rate of 98 ± 5.2%, 80% and 65%, respectively. Kellerin was effective in EC 50 as 38 mg/mL [89] .

Compounds having 3-hydroxycoumarin derivatives were also studied as antiviral agents but the results were somewhat not encouraging. This might be due to its non-conformity to the 4-HC pharmacophore. Way back in 1968 Giannella et al. reported some 2,4-dioxo-3-hydroxyiminochromane derivatives (125) showing good antiviral activity however, these compounds developed a high degree of cytotoxicity [90] . In order to lower their toxicity, the active molecule was modified while preserving the cyclic a-dicarbonyl structure and prepared several Mannich bases 4-N,N-dialkylaminomethyl-3-hydroxycoumarins (126). Preliminary examination of these compounds did not show any appreciable antiviral activity (Fig. 26 ) [91] . However, the 4-bromobenzylidene derivative of bis(4-hydroxycoumarin) (127) were found to exert some inhibitory activity against HSV-1 (KOS), HSV-2 (G), vaccinia virus and HSV-1 TK-KOS (ACVr) in the range of 9e12 mM [92] .

In continuation of studies on hybrid coumarin-benzimidazole and their appealing anti-HCV activity, Hwu et al. investigated a number of new hybrid compounds of uracilecoumarinearenes as potential inhibiting agents for chikungunya virus (CHIKV) (Fig. 27) . A set of doubly (uracilecoumarin) and triply conjugates (uracilecoumarinearenes) were evaluated to establish their SAR. The extension of the doubly conjugated uracilecoumarins to triply conjugated uracilecoumarinearenes by use of the eSO2e linker was vital to their anti-CHIKV activity. Bezouracil derivatives (128) had better selectivity indexes as compared to uracil (129) or thymine [93] .

Pohjala et al. screen around 356 natural compounds and clinically approved drugs against the chikungunya virus (CHIKV) replicon cell line and Semliki Forest virus (SFV) an alpha virus in 96well format. One of the coumarin anti-SFV screening hits exhibited Thenoyl derivative (131) was also effective against CHIKV (Fig. 28 ) [94] .

The present review aims to provide an important insight into the design of newer coumarin based antiviral agents. Since the 1990s, significant researches have been devoted to the development of antiviral coumarins. A diverse class of natural, semisynthetic and synthetic coumarin analogues have been reported as promising antiviral agents effective against the broad spectrum of viruses. Among these natural coumarins remain a fascinating rich source of lead compounds and boast ingenious functionalized motifs and proven to be important precursors to many effective antiviral drugs. Several classes of coumarins which were abandoned can be further improved in terms of efficacy and selectivity for the target or achieving optimal pharmacokinetic and pharmacodynamic properties. Given all these promising results and the potential antiviral activity, coumarins could be used in future in the clinic. Moreover, this review will surely provide a new horizon for research on antiviral agents and give better understanding of role of these molecules in diseases and how therapeutic agents could be most effective.

The authors confirm that this article content has no conflicts of interest.

Emerging Infectious Diseases: MERS-COV, Avian Influenza Remind us of the Ongoing Challenge

Emerging infectious diseases in 2012: 20 years after the institute of medicine report

Emerging virus diseases: can we ever expect the unexpected?

History, pharmacokinetics, and pharmacology of acyclovir

HIV drug resistance: problems and perspectives

Plant derived antivirals: a potential source of drug development

Advances in Structure and Activity Relationship of Coumarin Derivatives

New insights into the chemistry and antioxidant activity of coumarins

Structure-activity relationships of synthetic coumarins as HIV-1 inhibitors

Coumarins as inhibitors of HIV reverse transcriptase

Recent progress in the development of coumarin derivatives as potent anti-HIV agents

Medical Microbiology

Antiviral agents: structural basis of action and rational design

New antiretroviral agents: looking beyond protease and reverse transcriptase

Molecular targets for antiviral agents

Vipirinin, a coumarin-based HIV-1 Vpr inhibitor, interacts with a hydrophobic region of VPR

A player of many parts: the spotlight falls on thrombins structure

Viral proteases: evolution of diverse structural motifs to optimize function

Effect of the oral anticoagulant, warfarin, on HIV-1 replication and spread

Structure-based design of HIV protease inhibitors: 4-hydroxycoumarins and 4-hydroxy-2-pyronesas non-peptidic inhibitors

Structure-based design of novel HIV protease inhibitors: carboxamide-containing 4-hydroxycoumarinsand 4-hydroxy-2-pyrones as potent nonpeptidic inhibitors

Fig. 28. 7-Diethylamino coumarins effective against chikungunya virus

Use of medium-sized cycloalkyl rings to enhance secondary binding: discovery of a new class of Human Immunodeficiency Virus (HIV) protease inhibitors

Structure-based design of nonpeptidic HIV protease inhibitors from a cyclooctylpyranone lead structure

Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors

Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyranones

Cycloalkylpyranones and cycloalkyldihydropyrones as HIV protease inhibitors: exploring the impact of ring size on structure-activity relationships

Structure-based discovery of Tipranavir disodium (PNU-140690E): a potent, orally bioavailable, nonpeptidic HIV protease inhibitor

Competitive inhibition of HIV-1 protease by 4-hydroxy-benzopyran-2-ones and by 4-hydroxy-6-phenylpyran-2-ones

A novel nonpeptide HIV-1 protease inhibitor: elucidation of the binding mode and its application in the design of related analogs

Novel series of achiral, low molecular weight, and potent HIV-1 protease inhibitors

Nonpeptidic potent HIV-1 protease inhibitors:(4-hydroxy-6-phenyl-2-oxo-2h-pyran-3-yl)thiomethanes that span P1-P2 0 subsites in a unique mode of active site binding

Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic inhibitors

4-Hydroxy-5,6-dihydropyrones. 2. Potent non-peptide inhibitors of HIV protease

Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: a lead HIV protease inhibitor

Discovery and optimization of nonpeptide hiv-1 protease inhibitors

Discovery of novel, non-peptide HIV-1 protease inhibitors by pharmacophore searching

Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease

Coumarin-based inhibitors of HIV integrase

Structure-activity relationships of some 3-substituted-4-hydroxycoumarins as HIV-1 protease inhibitors

Synthesis and inhibiting activity of some 4-hydroxycoumarin derivatives on HIV-1 protease

3 0 ,4 0 -Di-o-(À)-camphanoyl-(þ)-ciskhellactone and related compounds: a. new class of potent anti-HIV agents

Coumarins I: isolation, purification, and structure determination of pteryxin and suksdorfin

Anti-AIDS agents. 15. Synthesis and anti-hiv activity of dihydroseselins and related analogs

Anti-AIDS agents 28. Synthesis and anti-HIV activity of methoxy substituted 3 0 ,4 0 -di-O-(-)-camphanoyl-(þ)-cis-khellactone (DCK) analogues

Anti-AIDS agents 31.1 synthesis and anti-HIV activity of 4-substituted 3 0 ,4 0 -di-O-(À)-camphanoyl-(þ)-cis-khellactone (DCK) thiolactone analogs

Anti-aids agents 33.1 Synthesis and anti-HIV activity of mono-methyl substituted 3 0 ,4 0 -di-O-(À)-camphanoyl-(þ)-cis-khellactone (DCK) analogues

Anti-AIDS agents. Part 47: synthesis and anti-HIV activity of 3-substituted 3 0 ,4 0 -Di-O-(S)-camphanoyl-(3 0 R,4 0 R)-(þ)-cis-khellactone derivatives

Anti-AIDS Agents. 37. Synthesis and structure-activity relationships of(3¢R,4¢R)-(þ)-cis-khellactone derivatives as novel potent anti-HIV Agents

Anti-AIDS agents 52. synthesis and anti-hiv activity of hydroxymethyl (3 0 R,4 0 R)-3 0 , 4 0 -Di-O-(S)-camphanoyl-(þ)-cis-khellactone (DCK) derivatives

Anti-AIDS agents 82: synthesis of seco-(3 0 R,4 0 R)-3 0 ,4 0 -di-O-(S)-camphanoyl-(þ)-cis-khellactone (DCK) derivatives as novel anti-HIV agents

Substituted 3 0 R,4 0 R-Di-O-(-)-camphanoyl-2 0 ,2 0 -dimethyldihydropyrano[2,3-f]chromone (DCP) analogues as potent anti-HIV agents

Anti-AIDS agents 86. Synthesis and anti-HIV evaluation of 2 0 ,3 0 -seco-3 0 -nor DCP and DCK analogues

Anti-AIDS agents 85. Design, synthesis, and evaluation of 1R,2R-dicamphanoyl-3,3-dimethyldihydropyrano-[2,3-c]xanthen-7(1H)-one (DCX) derivatives as novel anti-HIV agents

The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum

Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (±)-Calanolide A and its enantiomers

The inophyllums, novel inhibitors of HIV-1 reverse transcriptase isolated from the malaysian tree, Calophyllum inophyllum Linn

Inhibition of human immunodeficiency virus type 1 reverse transcriptase activity by cordatolides isolated from Calophyllum cordatooblongum

Structural analogues of the calanolide Anti-HIV Agents. modification of the trans-10,11-dimethyldihydropyran-12-ol ring (ring C)

Chemical library and structureeactivity relationships of 11-demethyl-12-oxo calanolide A analogues as anti-HIV-1 agents

Highly suppressing wild-type HIV-1 and Y181C mutant HIV-1 strains by 10-chloromethyl-11-demethyl-12-oxo-calanolide A with druggable profile

Coumarins and bicoumarin from Ferula sumbul: anti-HIV activity and inhibition of cytokine release

Chemical constituents of Prangos tschimganica structure elucidation and absolute configuration of coumarin and furanocoumarin derivatives with anti-HIV activity

Imperatorin inhibits HIV-1 replication through an Sp1-dependent pathway

Transcriptional suppression of the HIV promoter by natural compounds

3-Phenylcoumarins as inhibitors of HIV-1 replication

Vipirinin, a coumarin-based HIV-1 Vpr inhibitor, interacts with a hydrophobic region of VPR

Mesuol, a natural occurring 4-phenylcoumarin, inhibits HIV-1 replication by targeting the NF-kappa B pathway

Alcami, 4-Phenylcoumarins as HIV transcription inhibitors

Monte carlo method based qsar modeling of coumarin derivates as potent HIV-1 integrase inhibitors and molecular docking studies of selected 4-phenyl hydroxycoumarins

Synthesis and biological investigations of new thiazolidinone and oxadiazoline coumarin derivatives

Synthesis and in vitro anti-HIV activity of N-1,3-benzo[d]thiazol-2-yl-2-(2-oxo-2H-chromen-4-yl)acetamide derivatives using MTT method

Lamellarin R 20-sulfate, an inhibitor of HIV-1 integrase active against HIV-1 virus in cell culture

New constituents and antiplatelet aggregation and anti-HIV principles of Artemisia capillaris

Synthesis of new benzimidazole-coumarin conjugates as antihepatitis C virus agents

Structure-activity relationship of new anti-hepatitis C virus agents: heterobicycle-coumarin conjugates

Coumarin-purine ribofuranoside conjugates as new agents against hepatitis C virus

Synthesis and structureactivity relationships of imidazole-coumarin conjugates against hepatitis C virus

Coumarins hinged directly on benzimidazoles and their ribofuranosides to inhibit hepatitis C virus

Synthesis of novel imidazo[1,2-a]pyridine-4-hydroxy-2H-coumarins by Groebke-Blackburn-Bienayme multicomponent reaction as potential NS5B inhibitors

Novel anilinocoumarin derivatives as agents against hepatitis C virus by the induction of IFN-mediated antiviral responses

Activity of Mannich bases of 7-hydroxycoumarin against flaviviridae

Coumarins and anti-HBV constituents from Zanthoxylum schinifolium

No€ el, Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors

Anti-influenza drug discovery: structure-activity relationship and mechanistic insight into novel angelicin derivatives

BPR2-D2 targeting viral ribonucleoprotein complex-associated function inhibits oseltamivir-resistant influenza viruses

Inhibition of HIV-1 Tat-mediated transcription by a coumarin derivative, BPRHIV001, through the Akt pathway

Synthesis of toddacoumaquinone, a coumarinnaphthoquinone dimer, and its antiviral activities

Antiviral activity of (þ)-rutamarin against Kaposi's sarcoma-associated herpesvirus by inhibition of the catalytic activity of human topoisomerase II

Antiviral evaluation of sesquiterpene coumarins from Ferula assafoetida against HSV-1, Iran

Studies in the field of substances with antiviral activity. Derivatives of 2,4-dioxo-3-oxyiminochromane

Researches in the field of antiviral compounds. Mannich bases of 3-hydroxycoumarin

Benzylidene-bis-(4-hydroxycoumarin) and benzopyrano-coumarin derivatives: synthesis, 1 H/ 13 C-NMR conformational and X-ray crystal structure studies and in vitro antiviral activity evaluations

Benzouracil-coumarin-arene conjugates as inhibiting agents for chikungunya virus

Inhibitors of alphavirus entry and replication identified with a stable Chikungunya replicon cell line and virus-based assays

The authors wish to express their gratitude and appreciation to School of Chemical Science, Universiti Sains Malaysia, Penang for supporting this work. This work was funded through Research Grant No. (FRGS/203/6711462).